Table I.
Effects of ezetimibe in monotherapy on LDL size and subclasses in hypercholesterolaemic patients (modified from [9])
| Authors | Year | Dose [mg/day] | Duration [weeks] | Patients (n) | Selection criteria | Benefit |
|---|---|---|---|---|---|---|
| Farnier et al. Tribble et al |
2005 2008 |
10 | 12 | 165 | mixed hyperlipidaemia without CHD | partial |
| Geiss et al. | 2006 | 10 | 5 | 20 | severe hyperlipoproteinaemiaand CHD | no |
| Kalogirou et al. | 2007 | 10 | 16 | 50 | primary dyslipidaemia | no |
| Ose et al. | 2007 | 10 | 12 | 138 | primary hypercholesterolaemia | no |
| Nakou et al. | 2008 | 10 | 24 | 86 | overweight and obese subjectswith hypercholesterolaemia | yes |
CHD – coronary heart disease